In this Section |
153207 Computer-assisted alcohol and other drug screening of trauma patients: Results of a pilot studyTuesday, November 6, 2007
Screening for alcohol and other drugs (AOD) in trauma centers and emergency departments is recommended for early identification and appropriate referral and treatment of AOD abusers. This paper documents the development and pilot testing of a computerized screening instrument for trauma patients, using Adobe Professional 7.0 and Microsoft PowerPoint. The automated screener incorporates questions from NIAAA Alcohol Use Recommendations, CAGE, AUDIT, DAST-10, Skinner Trauma Scale, Readiness to Change Scale, Attribution of Injury and Perception of Pain and Level of Stress indexes, to screen for AOD abuse and dependence. The screener was delivered anonymously to a sample of 57 WVU adult trauma patients on a Motion touch screen tablet computer over a period of 11 days. The acceptability of computerized screening was high, with the vast majority of patients assessing the experience as positive and being willing to repeat it in future. Patients found the tablet screening easy, and the instrument just the right length. Only 6% preferred pencil and paper and 26% face-to-face versions, while 16% offered suggestions for improvement. In multivariate analysis of the pilot data, screening positive for AOD abuse or dependence (AUDIT score=8+ or DAST score=2+) was predicted by higher perceived stress/pain levels and attribution of responsibility for the injury to own AOD use (attribution) (OR=5.6 and 19.3, respectively), while high readiness to change was predicted by being uninsured and higher likelihood of attribution (OR = 5.8 and 29.7, respectively). Implications for designing and using computerized screening in EDs and trauma centers are discussed.
Learning Objectives: Keywords: Screening, Computer-Assisted
Presenting author's disclosure statement:
Any relevant financial relationships? No I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.
See more of: Screening and Detection; Access and Outcomes
See more of: Alcohol, Tobacco, and Other Drugs |